Academic literature on the topic 'Roflumilast'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Roflumilast.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Roflumilast"

1

Yosipovitch, Gil, Shawn Kwatra, James Del Rosso, et al. "Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast." SKIN The Journal of Cutaneous Medicine 9, no. 4 (2025): s587. https://doi.org/10.25251/579nct27.

Full text
Abstract:
Background: Pruritus is a burdensome symptom affecting quality of life (QOL) in patients with seborrheic dermatitis (SD), psoriasis, and atopic dermatitis (AD). Phosphodiesterase4 (PDE4) inhibitors may reduce pruritus by reducing inflammatory itch mediators. Topical roflumilast, formulated as a water-based foam or cream without penetration enhancers or fragrances, is a selective, highly potent PDE4 inhibitor. Efficacy and safety of once-daily, topical roflumilast has been demonstrated in patients with psoriasis (cream 0.3% and foam 0.3%), SD (foam 0.3%), and AD (0.15% and 0.05% cream). Methods
APA, Harvard, Vancouver, ISO, and other styles
2

Livingston, Nicholas R., Peter CT Hawkins, James Gilleen, et al. "Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia." Journal of Psychopharmacology 35, no. 9 (2021): 1099–110. http://dx.doi.org/10.1177/02698811211000778.

Full text
Abstract:
Background: Cognitive flexibility deficits are present in patients with schizophrenia and are strong predictors of functional outcome but, as yet, have no pharmacological treatments. Aims: The purpose of this study was to investigate whether the phosphodiesterase type-4 inhibitor, roflumilast, can improve cognitive flexibility performance and functional brain activity in patients with schizophrenia. Methods: This was a within-subject, randomised, double-blind, placebo-controlled, three-period crossover study using a version of the Intradimensional/Extradimensional (ID/ED) task, optimised for f
APA, Harvard, Vancouver, ISO, and other styles
3

Alispahic, Imane Achir, Rikke Sørensen, Josefin Eklöf, et al. "Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations." Journal of Clinical Medicine 9, no. 5 (2020): 1442. http://dx.doi.org/10.3390/jcm9051442.

Full text
Abstract:
Roflumilast is given as an add-on to inhalation medication in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis. Animal experiments have documented deleterious effects of roflumilast in bacterial infections, but trials have not reported the risk of bacterial infections in patients. The objective of this study is to determine, among outpatients with severe COPD in a two-year follow-up period, the risk of hospitalization-requiring pneumonia, severe acute exacerbation in COPD (AECOPD-hosp), and death. Patients with COPD using roflumilast (roflumilast users) were co
APA, Harvard, Vancouver, ISO, and other styles
4

Nicolas, Samar E., Michael D. Bear, Abir O. Kanaan, Oana Andreia Coman, and Lorena Dima. "Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis." American Journal of Therapeutics 30, no. 6 (2023): e535-e542. http://dx.doi.org/10.1097/mjt.0000000000001678.

Full text
Abstract:
Background: Plaque psoriasis is a chronic dermatologic autoimmune disease that affects adults and children. Roflumilast 0.3% cream is currently the only topical phosphodiesterase 4 inhibitor indicated for the treatment of plaque psoriasis in patients 12 years or older. Pharmacodynamics and Pharmacokinetics: Roflumilast inhibits phosphodiesterase 4 inhibitor enzyme leading to the accumulation of cyclic adenosine monophosphate, which suppresses the inflammatory mediators interferon-γ and tumor necrosis factor-α. Roflumilast, applied once daily, reaches steady state by day 15 and has a half life
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Roflumilast." Drugs in R & D 5, no. 3 (2004): 176–81. http://dx.doi.org/10.2165/00126839-200405030-00009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sanford, Mark. "Roflumilast." Drugs 70, no. 12 (2010): 1615–27. http://dx.doi.org/10.2165/11205930-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Christie, P. "Roflumilast." Drugs of Today 41, no. 10 (2005): 667. http://dx.doi.org/10.1358/dot.2005.41.10.920428.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cada, Dennis J., Terri L. Levien, and Danial E. Baker. "Roflumilast." Hospital Pharmacy 46, no. 8 (2011): 597–606. http://dx.doi.org/10.1310/hpj4608-597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fabbri, Leonardo M., Bianca Beghé, Uma Yasothan, and Peter Kirkpatrick. "Roflumilast." Nature Reviews Drug Discovery 9, no. 10 (2010): 761–62. http://dx.doi.org/10.1038/nrd3276.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sorbera, L. A., P. A. Leeson, and J. Castañer. "Roflumilast." Drugs of the Future 25, no. 12 (2000): 1261. http://dx.doi.org/10.1358/dof.2000.025.12.604045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Roflumilast"

1

Walsh, Nicola Margaret. "Comparison of the modes of action of Apremilast and Roflumilast." Thesis, University of Glasgow, 2015. http://theses.gla.ac.uk/7427/.

Full text
Abstract:
The phosphodiesterase 4 (PDE4) family are cAMP specific phosphodiesterases that play an important role in the inflammatory response and is the major PDE type found in inflammatory cells. A significant number of PDE4 specific inhibitors have been developed and are currently being investigated for use as therapeutic agents. Apremilast, a small molecule inhibitor of PDE 4 is in development for chronic inflammatory disorders and has shown promise for the treatment of psoriasis, psoriatic arthritis as well as other inflammatory diseases. It has been found to be safe and well tolerated in humans and
APA, Harvard, Vancouver, ISO, and other styles
2

Rieder, Florian. "Wirkung der spezifischen Phosphodiesterase-Inhibitoren Roflumilast und Pumafentrine im Mausmodell der Dextran-Sodium-Sulfat-induzierten Kolitis." Diss., lmu, 2004. http://nbn-resolving.de/urn:nbn:de:bvb:19-28038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Приступа, Людмила Никодимівна, Людмила Никодимовна Приступа, Liudmyla Nykodymivna Prystupa та Ф. О. Красненко. "Ефективність рофлуміласту у хворих на хронічне обструктивне захворювання легень із ожирінням". Thesis, Сумський державний університет, 2017. http://essuir.sumdu.edu.ua/handle/123456789/55445.

Full text
Abstract:
Зниження активності фосфодіестерази-4 (ФДЕ-4) – інноваційний підхід у лікуванні хронічного обструктивного захворювання легень (ХОЗЛ) з метою зменшення активності хронічного запалення. Рофлуміласт – високоселективний інгібітор ФДЕ-4, зареєстрований як додатковий засіб до терапії пацієнтів із ХОЗЛ. Завдяки унікальному механізму дії, рофлуміласт покращує функцію легень та зменшує частоту загострень. Метою роботи було визначення клінічної ефективності рофлуміласту у хворих на ХОЗЛ із ожирінням.
APA, Harvard, Vancouver, ISO, and other styles
4

Victoni, Tatiana. "Etude de l'activation de cellules pulmonaires par un extrait de fumée de cigarette ou par l'élastase du neutrophile associés au lipopolysaccharideEtude des effets d'un inhibiteur de phophodiestérase de type 4, le roflumilast." Phd thesis, Université Rennes 1, 2013. http://tel.archives-ouvertes.fr/tel-00950306.

Full text
Abstract:
La bronchopneumopathie chronique obstructive (BPCO) est une maladie caractérisée par une réaction inflammatoire intense avec une destruction du parenchyme pulmonaire et une perte d'élasticité du poumon conduisant à une obstruction quasi-irréversible des voies aériennes. L'utilisation du tabac est le principal facteur de risque de cette maladie. La fumée de cigarette active les cellules épithéliales et les macrophages résidents en libérant des protéases et des chimiokines. Ces phénomènes sont responsables de l'infiltration de cellules inflammatoires dans le poumon, telles que les neutrophiles,
APA, Harvard, Vancouver, ISO, and other styles
5

Fernandes, Diogo Miguel Pereira. "Inibidores seletivos e não seletivos da fosfodiesterase no tratamento da DPOC." Master's thesis, 2018. http://hdl.handle.net/10316/82803.

Full text
Abstract:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina<br>COPD is nowadays the world’s 4th cause of death with a prevision that in 2020 it becames the 3rd. In Portugal the estimated prevalence is 14,2%, leading to 8000 annual deaths. It is an important public health issue that requires a lot of health resources. COPD is characterized by a progressive and irreversible airflow limitation, with a combination of lung destruction and small airways obstruction. Inflammation is one of the major mechanisms that induce the disease and tobacco is the major and preventable c
APA, Harvard, Vancouver, ISO, and other styles
6

Rieder, Florian [Verfasser]. "Wirkung der spezifischen Phosphodiesterase-Inhibitoren Roflumilast und Pumafentrine im Mausmodell der Dextran-Sodium-Sulfat-induzierten Kolitis / vorgelegt von Florian Rieder." 2004. http://d-nb.info/972835911/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Roflumilast"

1

Verfasser, Schließmann Stephan J., Kirschbaum Andreas Verfasser, Plönes Till 1976 Verfasser, et al., eds. Roflumilast-N-oxide induces surfactant protein expression in human alveolar epithelial cells type II. Universität, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Blokdijk, G. J. Roflumilast; Complete Self-Assessment Guide. CreateSpace Independent Publishing Platform, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Roflumilast"

1

Graham, Garry G., and Kevin D. Pile. "Phosphodiesterase 4 Inhibitors: Apremilast and Roflumilast." In Compendium of Inflammatory Diseases. Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_56.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Graham, Garry G., and Kevin D. Pile. "Phosphodiesterase 4 Inhibitors: Apremilast and Roflumilast." In Encyclopedia of Inflammatory Diseases. Springer Basel, 2015. http://dx.doi.org/10.1007/978-3-0348-0620-6_56-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Medvedova, I., M. Prso, A. Eichlerova, D. Mokra, P. Mikolka, and J. Mokry. "Influence of Roflumilast on Airway Reactivity and Apoptosis in Ovalbumin-Sensitized Guinea Pigs." In Advances in Experimental Medicine and Biology. Springer International Publishing, 2014. http://dx.doi.org/10.1007/5584_2014_77.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Roflumilast." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-1525.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Roflumilast." In Checkliste Arzneimittel A–Z, edited by Detlev Schneider and Frank Richling. Georg Thieme Verlag, 2013. http://dx.doi.org/10.1055/b-0034-82738.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Roflumilast to Simeticon." In Checkliste Arzneimittel A - Z, edited by Schneider and Richling. Georg Thieme Verlag, 2017. http://dx.doi.org/10.1055/b-0037-144509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ruiz Briones, Paula, María Sagrario Pernia López, Félix Jesús García Moreno, et al. "Validación galénica y experiencia clínica de una pomada de Roflumilast 0,166mcg/g en orobase para tratamiento de aftas orales persistentes." In Libro de comunicaciones 69 Congreso SEFH. Sociedad Española de Farmacia Hospitalaria, 2024. http://dx.doi.org/10.62917/24.69.0712.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Roflumilast"

1

Kammerer, Susanne. "Topical roflumilast beneficial in atopic dermatitis." In American Academy of Dermatology 2023, edited by Peter van de Kerkhof. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/194ffc74.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rhee, Chin Kook, Jee Hye Kim, Shin Young Kim, Chan Kwon Park, and Hyoung Kyu Yoon. "Effect of roflumilast on neutrophilic asthma model." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa1147.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Savelikhina, Iryna, Mykola Ostrovskyy, Kseniia Ostrovska, Mariana Kulynych-Miskiv, Oleksandr Varunkiv, and Kostiantyn Shvets. "Biomarkers in COPD: Beneficial effects of roflumilast." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa1071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rhee, Chin Kook, Yong Bum Park, and Hyoung Kyu Yoon. "Risk factors for discontinuation of roflumilast in COPD patients." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa1060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Stanford, D., L. W. Rasmussen, J. LaFontaine, A. Allen, E. L. Burnham, and S. V. Raju. "Roflumilast Reverses Alcohol Impairment of CFTR Function and Mucus Clearance." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1896.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Domvri, Kalliopi, Konstantinos Porpodis, Antonis Papaioannou, et al. "Neutrophils and spirometry changes in COPD patients treated with roflumilast." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa3979.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kammerer, Susanne. "Roflumilast foam led to high response rates in seborrheic dermatitis." In EADV Congress 2022, edited by Peter van de Kerkhof. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/b3195d65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Feineis, Martin, Charlott Terschluse, Louis Jouanjan, Björn Frye, and Dajana Stolz. "Roflumilast in sarcoidosis: A retrospective analysis of 51 sarcoidosis patients." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa2476.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Watz, Henrik, Nitin Bagul, Ken Nip, et al. "Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE)." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa308.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hanania, Nicola A., Mark T. Dransfield, Udo-Michael Goehring, Hassan Lakkis, and Paul Rowe. "Efficacy Of Roflumilast In Elderly Patients With Chronic Obstructive Pulmonary Disease." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!